Unlike its big pharma peers, Sanofi-Aventis will not build a research center in China. Instead, the company will seek to establish half a dozen research partnerships with China universities and state-sponsored research institutions. Potential targets mentioned for the research were cancer and rheumatoid arthritis. Dr. Marc Cuzel, head of R&D for Sanofi-Aventis, said that the advantage of working with existing institutions is the innovation that is already there. More details...

Stock Symbol: (NYSE: SNY)